Takara Bio USA, Inc.

Takara Bio USA, Inc. is a leading biotechnology company specializing in the development, manufacturing, and distribution of reagents, kits, instruments, and services for life science research. The company's mission is to accelerate scientific discovery and improve the human condition through innovative biotechnology tools. Headquartered in San Jose, California, Takara Bio USA, Inc. operates as a wholly-owned subsidiary of Takara Bio Inc., a global leader in biotechnology research and development based in Japan.

Takara Bio USA's extensive portfolio supports advancements across various life science disciplines, including genomics, molecular biology, and cellular technologies. Key product areas encompass next-generation sequencing (NGS), polymerase chain reaction (PCR), gene delivery, genome editing, single-cell and spatial transcriptomics, nucleic acid and protein purification, and stem cell research. The company also provides automated sample preparation solutions and contract development and manufacturing (CDMO) services for regenerative medicine products and genetic analysis, serving academic institutions, federal research bodies, and pharmaceutical companies.

In recent leadership changes, Andrew Farmer was appointed President and CEO in July 2026, succeeding Carol Lou upon her retirement. The company continues to be recognized for its innovation, notably winning "The Scientist's Top Innovations Award" in 2026 for its Trekker FX Single-Cell Spatial Mapping Kit, a platform-agnostic spatial biology solution. Takara Bio USA has expanded its capabilities through strategic acquisitions, including Curio Bioscience in spatial genomics, and previously Rubicon Genomics and WaferGen Bio-systems, reinforcing its market position as a key provider in the biotechnology sector.